Recent News

• 02.04.2026 - Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
• 01.29.2026 - Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
• 01.08.2026 - Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
• 01.05.2026 - Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference
• 12.18.2025 - Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

Recent Filings

• 01.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 144 Report of proposed sale of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.07.2026 - 144 Report of proposed sale of securities
• 01.07.2026 - 144 Report of proposed sale of securities
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities